Hien T T Pham1, Geert A Ten Kate1,2, Lubbert Dijkhuizen1,3, Sander S van Leeuwen1,4. 1. Microbial Physiology, Groningen Biomolecular Sciences and Biotechnology Institute (GBB) , University of Groningen , Nijenborgh 7 , 9747 AG Groningen , The Netherlands. 2. Eurofins Carbohydrate Competence Centre , 8440 AT Heerenveen , The Netherlands. 3. CarbExplore Research BV , Zernikepark 12 , 9747 AN Groningen , The Netherlands. 4. Laboratory Medicine , University Medical Center Groningen , Hanzeplein 1 , 9713 GZ Groningen , The Netherlands.
Abstract
Sialylated oligosaccharides contribute 12.6-21.9% of total free oligosaccharides in human milk ( hMOS). These acidic hMOS possess prebiotic properties and display antiadhesive effects against pathogenic bacteria. Only limited amounts of sialylated hMOS are currently available. The aim of our work is to enzymatically synthesize sialylated oligosaccharides mimicking hMOS functionality. In this study, we tested mixtures of glucosylated-lactose (GL34), galactosylated-lactulose (LGOS), and galacto-oligosaccharide (Vivinal GOS) molecules, as trans-sialylation acceptor substrates. The recombinant trans-sialidase enzyme from Trypanosoma cruzi (TcTS) was used for enzymatic decoration, transferring (α2→3)-linked sialic acid from donor substrates to nonreducing terminal β-galactopyranosyl units of these acceptor substrates. The GL34 F2 2-Glc-Lac compound with an accessible terminal galactosyl residue was sialylated efficiently (conversion degree of 47.6%). TcTS sialylated at least 5 LGOS structures and 11 Vivinal GOS DP3-4 compounds. The newly synthesized sialylated oligosaccharides are interesting as potential hMOS mimics for applications in biomedical and functional-food products.
Sialylated oligosaccharides contribute 12.6-21.9% of total free oligosaccharides in human milk ( hMOS). These acidic hMOS possess prebiotic properties and display antiadhesive effects against pathogenic bacteria. Only limited amounts of sialylated hMOS are currently available. The aim of our work is to enzymatically synthesize sialylated oligosaccharides mimicking hMOS functionality. In this study, we tested mixtures of glucosylated-lactose (GL34), galactosylated-lactulose (LGOS), and galacto-oligosaccharide (VivinalGOS) molecules, as trans-sialylation acceptor substrates. The recombinant trans-sialidase enzyme from Trypanosoma cruzi (TcTS) was used for enzymatic decoration, transferring (α2→3)-linked sialic acid from donor substrates to nonreducing terminal β-galactopyranosyl units of these acceptor substrates. The GL34 F2 2-Glc-Lac compound with an accessible terminal galactosyl residue was sialylated efficiently (conversion degree of 47.6%). TcTS sialylated at least 5 LGOS structures and 11 VivinalGOS DP3-4 compounds. The newly synthesized sialylated oligosaccharides are interesting as potential hMOS mimics for applications in biomedical and functional-food products.
In human milk, free
oligosaccharides constitute the third-most-abundant
component after lactose and fat. Human milk oligosaccharides (hMOS) represent lactose molecules elongated with N-acetylglucosamine (GlcNAc), galactose (Gal), fucose (Fuc),
and N-acetylneuraminic acid (Neu5Ac) with various
glycosidic-linkage types.[1] Sialic acid
can be coupled to galactose residues in hMOS with
(α2→3) or (α2→6) linkages and to GlcNAc
with (α2→6) linkages. These sialylated oligosaccharides
contribute 12.6–21.9% of total hMOS.[2] There is increasing evidence for positive functional
effects from this group of acidic oligosaccharides on human health.[3−5] Specific hMOS structures, namely, disialyllacto-N-tetraose and 2′-fucosyllactose, prevented and reduced
necrotizing enterocolitis (NEC) in neonatal rats and thus may be used
to prevent NEC in formula-fed infants.[6,7] Preventive
effects against NEC were also observed with a Sia-GOS mixture, particularly
with disialylated GOS.[7,8] 3′-Sialyllactose stimulates
growth of various Bifidobacterium strains, including
the infant-gut-related Bifidobacterium longum subsp. infantis.[9] Sialylated oligosaccharides
also prevent intestinal attachment of pathogens by acting as receptor
analogues, competing with epithelial ligands for bacterial binding.[10−14] Compared with human milk, free oligosaccharides in the milk of domesticated
animals are much less abundant.[15] Bovine
milk, for instance, has only trace amounts of milk oligosaccharides.[16,17] The natural scarcity of these highly bioactive sialylated oligosaccharides
stimulated us to study the possible synthesis of mimics via trans-sialylation
of β-galactose (β-Gal)-linked compounds in various oligosaccharide
mixtures. One example is the VivinalGOS mixture that is commercially
used in infant nutrition.[18,19]Recently, we
have reported the enzymatic synthesis of two novel
oligosaccharide mixtures (GL34 and LGOS) and their structural characterization.[20,21] GL34 is a mixture of five (α1→2/3/4)-glucosylated lactose
molecules, with a degree of polymerization (DP) of 3–4, synthesized
from sucrose as the donor substrate by glucansucrases (Gtf180-ΔN
and GtfA-ΔN) as biocatalysts (Scheme ).[20] The GL34
mixture exhibits selective stimulatory effects on the growth of various
strains of lactobacilli and bifidobacteria.[22] LGOS is a mixture of (β1→3/4/6)-galactosylated lactulose
molecules, with one or two galactosyl moieties, synthesized from lactulose
as the donor and acceptor substrate by wild-type and mutant β-galactosidase
enzymes from Bacillus circulans ATCC 31382 (Scheme ).[21] Previously, oligosaccharides derived from lactulose were
shown to promote the growth of bifidobacteria and to exert beneficial
effects on the digestive tract.[23−26]
Scheme 1
Schematic Presentation of All Structures in the GL34
Glucosylated-Lactose and LGOS Galactosylated-Lactulose Mixtures Used[20,21]
Lactose is galactosyl-glucose.
Lactulose is galactosyl-fructose.
Schematic Presentation of All Structures in the GL34
Glucosylated-Lactose and LGOS Galactosylated-Lactulose Mixtures Used[20,21]
Lactose is galactosyl-glucose.Lactulose is galactosyl-fructose.In view
of the potential functional properties of these novel GL34
and LGOSoligosaccharides we decided to try and further develop their
structures to better mimic acidic hMOS. In this study,
trans-sialidase from Trypanosoma cruzi (TcTS)[27] was employed for the trans-sialylation of oligosaccharides
in the GL34 and LGOS mixtures. Among trans-sialidases (EC 3.2.1.18), T. cruzi trans-sialidase is one of the best-studied enzymes.[27] It plays an important role in host-cell invasion
and pathogenicity of T. cruzi because of its ability
to scavenge and transfer sialic acid to the pathogen’s extracellular
mucins, thereby hiding the pathogen from the host immune system.[28,29]TcTS catalyzes trans-sialylation reactions via a ping-pong
mechanism,[30] which starts with formation
of a stable sialo-enzyme
intermediate through a covalent bond with the nucleophile Tyr342.[31] This is followed by transfer of the sialic acid
to a β-Gal-linked acceptor substrate involving a nucleophilic
attack of the hydroxyl group at C3 of this β-Gal.[30] When a suitable β-Gal-linked acceptor
is absent, this enzyme catalyzes a hydrolysis reaction and sialic
acid is released.[32] In case of TcTS, sialyl
transfer is catalyzed with much greater efficiency than hydrolysis.[33] TcTS can use glycoproteins or oligosaccharides
as acceptor substrates, but it only uses compounds possessing sialic
acid (α2→3)-linked to a terminal β-Gal as donor
substrates.[33] In previous work, we showed
that TcTS catalyzes the transfer of sialic acid from a κ-casein-derived
glyco-macropeptide (GMP) donor substrate to galacto-oligosaccharides
(GOS).[8,34] However, a detailed analysis of these monosialylated
and disialylated GOS structures was not performed. GMP is a byproduct
of cheese manufacturing and contains a high levels of O-glycans, which carry Neu5Ac, including mainly Neu5Ac(α2→3)Gal(β1→3)GalNAc
and Neu5Ac(α2→3)Gal(β1→3)[Neu5Ac(α2→6)]GalNAc,
which can be used as donor substrates.[35,36]In this
study, we used the GL34 and LGOS mixtures as acceptor substrates
and GMP as the donor substrate. The negatively charged products were
fractionated using Dowex 1 × 8 chloride. Furthermore, we characterized
the sialylated GOS structures that were synthesized in our previous
work[8] in more detail. The decorated GL34,
GOS, and LGOS structures were identified using high-pH anion-exchange
chromatography (HPAEC), and one-dimensional 1H nuclear-magnetic-resonance
spectroscopy (1D1H NMR spectroscopy).
Materials and Methods
Chemicals and Materials
Bovine κ-casein-derived
glyco-macropeptide (GMP) was provided by the FrieslandCampina Innovation
Center. N-Acetylneuraminic acid (Neu5Ac), 2-O-(4-methylum-belliferyl)-α-N-acetylneuraminic
acid (4MU-Neu5Ac), and N-acetylneuraminyl(α2→3)lactose
(3′-SL) were obtained from Carbosynth Ltd. Neuraminidase from Clostridium perfringens was obtained from Roche. Synthesis
of glucosylated-lactose compounds (GL34),[20] galactosylated-lactulose compounds (LGOS),[21] and sialylated VivinalGOS (DP3 and DP4) compounds[8] has been reported previously.
TcTS Expression and Purification
Escherichia
coli BL21 (DE3) (Invitrogen) was used as the host for the
expression of the trans-sialidase from Trypanosoma cruzi. Precultures of E. coli BL21 (DE3) harboring pTrcTS611/2
were cultured overnight at 30 °C.[37,34] Terrific broth
(TrB) with 12 g of tryptone, 24 g of yeast extract, 4 mL of glycerol,
and 100 μg mL–1 ampicillin was inoculated
with 1% preculture at 30 °C and 200 rpm. Expression of trans-sialidase
was induced using 0.2 mM isopropyl β-d-thiogalactopyranoside
(IPTG) when the cell density reached A600 = 0.4–0.6. Cultivation was continued at 18 °C for 4
h. The cells were collected by centrifugation (10 min, 4 °C,
10 000g) and washed with 50 mM Tris-HCl buffer
(pH 8.0). Cell resuspension by B-Per Tris solution (Thermo Scientific,
Pierce) was followed by incubation at room temperature for 30 min.
The trans-sialidase enzyme was purified with an HIS-Select Nickel
Affinity Gel (Sigma). After 1.5 h of binding at 4 °C on a rotary
shaker, the bound protein was consecutively washed with Tris-HCl buffer
(50 mM, pH 8.0) containing NaCl (0.3 M) and imidazole (5 and 30 mM)
prior to its elution with 300 mM imidazole in the same buffer. Purified
TcTS enzyme was washed and concentrated in buffer Tris-HCl (pH 8.0)
using a Millipore filter (50k).
Enzyme Incubations
TcTS (5 μg mL–1) was incubated with various
concentrations (1, 5, and 10 mM) of
the GL34 mixture (average DP3) and 67.5 mg mL–1 GMP
(corresponding to 5 mM (α2→3)-linked Neu5Ac)[34] in 50 mM sodium citrate buffer (pH 5.0) at 25
°C for 24 h. The reactions were stopped by heating at 65 °C
for 10 min. Aliquots of 10 μL were diluted with 190 μL
of DMSO (95%) for HPAEC-PAD analysis.TcTS (5 μg mL–1) was incubated with various concentrations (1, 5,
10, and 15 mM) of the LGOS mixture (average DP3) and 67.5 mg mL–1 GMP (corresponding to 5 mM (α2→3)-linked
Neu5Ac)[34] in 50 mM sodium citrate buffer
(pH 5.0) at 25 °C. TcTS (5 μg mL–1) was
added to the incubation mixture at t = 0 h and after
each 24 h of incubation. Aliquots of 20 μL were sampled after
24, 48, and 72 h of incubation and mixed with 380 μL of DMSO
(95%) for analysis by HPAEC-PAD profiling. The reactions were stopped
by heating at 65 °C for 10 min.
Isolation of Negatively
Charged Oligosaccharides by Dowex Chromatography
Dowex 1
× 8 chloride (Cl–) (Sigma-Aldrich)
was packed in an Econo-column (1.5 × 10 cm, Biorad) and activated
with 10 column volumes (10 CV) of NaOH 2 M (at least 1 h contact time).
Before injection of samples, the column was equilibrated with 10 CV
of water. Elution of the sialylated oligosaccharides was performed
at a flow-rate of 1 mL min–1 with Milli-Q water
(MQ) and ammonium bicarbonate as eluents. After injection, unbound
compounds were removed from the column by washing with MQ for 3 CV.
Monosialylated and disialylated oligosaccharides were eluted with
3 CV of 50 and 400 mM ammonium bicarbonate, respectively. An extra
elution step with 500 mM ammonium bicarbonate was used to wash off
all remaining sialylated structures. The collected fractions were
lyophilized.
Desialylation of Sialylated Oligosaccharides
Fractions
of sialylated LGOS were treated with acetic acid (20%) for 1 h at
room temperature, which was followed by neutralization with 1 M NaOH.
Desialylated fractions were desalted using Carbograph SPE columns.Sialylated VivinalGOS fractions of DP3 and DP4 were desialylated
by incubation with 1 U mL–1 neuraminidase (Roche)
in 0.1 M acetate buffer (pH 5.0) at 37 °C for 24 h.
HPAEC-PAD Chromatography
Oligosaccharide mixtures were
analyzed by HPAEC-PAD profiling on a Dionex ICS-3000 system (Thermo
Scientific) equipped with a CarboPac PA-1 column (250 × 2 mm,
Dionex) and detected with a pulsed amperometric detector (PAD) using
a gold working electrode. Eluting glycans were detected using a standard
manufacturer’s quadruple-potential waveform for detecting carbohydrates.
Conversion of substrates into sialylated compounds was estimated by
comparing converted peaks with unconverted peaks (F1 and F3 for GL34,
Fru for LGOS) at different time points, calculating depletion of peaks.
A gradient of 30 to 600 mM sodium acetate in 0.1 M NaOH (0.25 mL min–1) was used for analytical separation of acidic oligosaccharides.
Another complex gradient of eluents A (100 mM NaOH), B (600 mM NaOAc
in 100 mM NaOH), C (Milli-Q water), and D (50 mM NaOAc) was used for
profiling neutral oligosaccharide mixtures as previously described.[20]
NMR Spectroscopy
Structures of the
transferred compounds
were determined by 1D1H NMR recorded at a probe temperature
of 25 °C on a Varian Inova 500 Spectrometer (NMR Center, University
of Groningen). The samples were exchanged twice with D2O (99.9 atom % D, Cambridge Isotope Laboratories, Inc.) with intermediate
lyophilization and then dissolved in 0.65 mL of D2O containing
acetone as the internal standard (δ 1H 2.225 ppm).
Data was recorded at 16k complex data points, and the HOD signal was
suppressed using a WET1D pulse (500 MHz spectra). MestReNova 9.1.0
(Mestrelabs Research SL) was used to process NMR spectra, using Whittaker
Smoother baseline correction.
Results and Discussion
Previously, N-acetylneuraminic acid (Neu5Ac) was
determined to be a major component (>99%) of the 3.6% (w/w) sialic
acid in GMP, in comparison with N-glycolylneuraminic
acid (Neu5Gc).[34] A concentration of 67.5
mg mL–1 GMP, corresponding to 5 mM (α2→3)-linked
Neu5Ac, was used as donor substrate for the incubations in this study.
At this fixed concentration of GMP as a donor substrate, the concentrations
of the acceptor substrates necessary to obtain their maximal conversion
degrees were determined. All the incubations were carried out under
the optimal conditions for TcTS as previously reported (in 50 mM sodium
citrate buffer pH 5.0 at 25 °C).[34,38]
Sialylation
of GL34 by TcTS
The mixture GL34 (average
DP3) was incubated at concentrations of 1, 5, and 10 mM, with 67.5
mg mL–1 GMP and 5 μg mL–1 TcTS at 25 °C and pH 5.0 for 24 h. After incubation, the HPAEC-PAD
profiles showed a new peak eluting at a retention time of ∼14.5
min, which is in the retention area of negatively charged oligosaccharides
in this gradient (Figure , spectrum 2).[8] In the HPAEC-PAD
profile of neutral oligosaccharides, only the F2-compound peak had
a significantly decreased area (Figure , spectrum 1). These results suggested that F2 was
used as an acceptor substrate for trans-sialylation by TcTS. The signals
of Neu5Ac(α2→3) (H-3e at δ 2.755 and H-3a at δ
1.795) were detected in the 1D1H NMR spectrum of the GL34
mixture after the trans-sialylation reaction (Figure S1). The presence of a new signal at δ 4.212
is fitting with the 3-substitution at the terminal galactosyl residue
of F2 with Neu5Ac (Figure S1), confirming
the synthesis of Neu5Ac(α2→3)Gal(β1→4)[Glc(α1→2)]Glc
(Scheme ). On the
basis of the HPAEC-PAD responses, the maximal conversion of F2 into
the corresponding sialylated-F2 was observed with 10 mM GL34 and calculated
as 47.6%, on the basis of reduction of the F2 peak. The data shows
that only F2 was used as an acceptor substrate for trans-sialylation
by TcTS. In the GL34 mixture, F2 is the only compound with an accessible
β-Gal residue at a nonreducing terminal position (Scheme ). TcTS was shown to also glycosylate
internal β-Gal residues in specific structures (i.e., in a Gal(β1→6)Gal
epitope),[27,30] but these are absent in GL34. F1 4′-Glc-Lac
and F4 2,4′-Glc-Lac, the only other GL34 compounds with nonsubstituted
OH-3 positions (on the internal galactose residue, Scheme ),[20] were not used as acceptor substrates.
Figure 1
HPAEC-PAD profiles of compounds in the GL34/GMP/TcTS reaction mixture
(incubation at 25 °C and pH 5.0, using 10 mM GL34) at t = 0 h (dotted line) and t = 24 h (solid
line) using a CarboPac PA-1 column with gradients for (1) neutral
oligosaccharides and (2) acidic oligosaccharides.
Scheme 2
Schematic Presentation
of the (α2→3)-Sialylation Product
of F2 (GL34 Mixture) and Possible Structures of the 5–8 (α2→3)-Sialylation
Products of the LGOS Mixture
HPAEC-PAD profiles of compounds in the GL34/GMP/TcTS reaction mixture
(incubation at 25 °C and pH 5.0, using 10 mM GL34) at t = 0 h (dotted line) and t = 24 h (solid
line) using a CarboPac PA-1 column with gradients for (1) neutral
oligosaccharides and (2) acidic oligosaccharides.
Sialylation of LGOS by TcTS
Various concentrations
of the LGOS mixture (1, 5, 10, and 15 mM) were incubated with 67.5
mg mL–1 GMP as a donor substrate and with TcTS (5
μg mL–1) at 25 °C and pH 5.0. Because
of the relatively low stability of this trans-sialidase,[38] extra TcTS (5 μg mL–1) was added to the incubation mixtures after every 24 h of incubation.
The incubation experiments were followed over time, and the highest
degree of LGOS conversion into sialylated LGOS was ∼52% after
48 h with 1 mM LGOS mixture (Figure ). Conversion of LGOS was estimated by following nonsialylated-LGOS-peak
depletion over time, assuming that all LGOS had similar response factors
on the PAD detector. At this LGOS concentration, the conversion degree
increased significantly from 37.4 to 52.0% when the incubation lasted
from 24 to 48 h (Figure ). In all cases, the GMP-derived Neu5Ac(α2→3) as the
donor substrate was not completely utilized, with a maximal use of
80% when incubated with 15 mM LGOS for 24 h. Enhanced conversion degrees
were not observed when incubating other concentrations of the LGOS
mixture longer than 24 h despite renewed addition of TcTS (Figures S2–S4).
Figure 2
Conversion of the LGOS-mixture
compounds into sialylated oligosaccharides
at different concentrations of LGOS and various incubation times,
with renewed addition of TcTS after each 24 h. Data obtained from
HPAEC-PAD responses (in duplicate).
Conversion of the LGOS-mixture
compounds into sialylated oligosaccharides
at different concentrations of LGOS and various incubation times,
with renewed addition of TcTS after each 24 h. Data obtained from
HPAEC-PAD responses (in duplicate).The HPAEC-PAD profiles of the incubation mixtures with 1
mM LGOS
showed development of several new peaks over time (Figure ). These new peaks eluted at
retention times between 12–22 min, indicating synthesis of
a complex mixture of sialylated LGOS. The negatively charged (Sia-LGOS)
oligosaccharides were separated from the neutral (LGOS) oligosaccharides
by Dowex 1 × 8 (Cl–) chromatography and then
reanalyzed by HPAEC-PAD profiling (Figure ). The neutral oligosaccharides in the unbound
Dowex fraction eluted during the first 12 min in the HPAEC-PAD profile
(Figure , spectrum
1). The Dowex fraction that eluted with 50 mM ammonium bicarbonate
(Sia-LGOS) eluted between 12 and 18 min in the HPAEC-PAD profile (Figure , spectrum 2), fitting
with monosialylated structures.[8] The Dowex
fraction containing disialylated structures was relatively minor,
limiting possibilities for further characterization.
Figure 3
HPAEC-PAD profiles of
compounds in the reaction mixtures of 1 mM
LGOS, 5 mM GMP-derived Neu5Ac(α2→3), and 5 μg mL–1 TcTS incubated at 25 °C and pH 5.0 for 0–72
h, with renewed addition of TcTS (5 μg mL–1) after each 24 h of incubation. Neutral LGOS and negatively charged
Sia-LGOS eluted at 2–12 and 12–18 min, respectively.
Figure 4
HPAEC-PAD profiles of the Dowex 1 × 8 (Cl–) chromatography fractions obtained by (1) MQ rinsing
(neutral oligosaccharides)
and (2) elution with 50 mM ammonium bicarbonate (Sia-LGOS). The reaction
mixture of 1 mM LGOS, 5 mM GMP-derived Neu5Ac(α2→3),
and 10 μg mL–1 TcTS, incubated at 25 °C
and pH 5.0 for 48 h, was used for Dowex chromatography.
HPAEC-PAD profiles of
compounds in the reaction mixtures of 1 mM
LGOS, 5 mM GMP-derived Neu5Ac(α2→3), and 5 μg mL–1 TcTS incubated at 25 °C and pH 5.0 for 0–72
h, with renewed addition of TcTS (5 μg mL–1) after each 24 h of incubation. Neutral LGOS and negatively charged
Sia-LGOS eluted at 2–12 and 12–18 min, respectively.HPAEC-PAD profiles of the Dowex 1 × 8 (Cl–) chromatography fractions obtained by (1) MQ rinsing
(neutral oligosaccharides)
and (2) elution with 50 mM ammonium bicarbonate (Sia-LGOS). The reaction
mixture of 1 mM LGOS, 5 mM GMP-derived Neu5Ac(α2→3),
and 10 μg mL–1 TcTS, incubated at 25 °C
and pH 5.0 for 48 h, was used for Dowex chromatography.The 1D1H NMR spectrum (Figure S5) of the negatively charged fraction
revealed signals at δ
2.760 and 1.803, which belong to the Neu5Ac H-3e and H-3a atoms, respectively,
of the Neu5Ac(α2→3) residues.[39] These NMR-spectroscopy data confirmed the sialylation of LGOS by
TcTS. To identify the compounds in the LGOS mixture that were decorated
with Neu5Ac, desialylation of these sialylated-LGOS was carried out
using 20% acetic acid.Comparison of the HPAEC-PAD profiles
of the desialyled fraction
with that of the LGOS mixture allowed identification of at least five
structures that were monosialylated by TcTS: LGOS2a or 2b, LGOS4,
LGOS5, LGOS6, and LGOS7a or 7b (Figure ). In the LGOS profile structures, LGOS4 and LGOS5
are the major components. After sialylation and desialylation, the
HPAEC-PAD profile showed LGOS6 and LGOS7 to be the predominant structures.
In the LGOS mixture, LGOS6 is only a trace peak, but in the sialylated
fraction, LGOS6 is the major structure. This indicated that the Gal(β1→3)Gal(β1→4)
epitope is very favorable for sialylation. The LGOS7 peak consisted
of two structures, one with a Gal(β1→3)Gal(β1→3)
epitope and one with a Gal(β1→4)Gal(β1→3)
epitope. Although it is not possible to distinguish between the two
structures, it is likely that structure LGOS7a, with a terminal Gal(β1→3)
residue, is the mainly sialylated LGOS7 structure. This fits with
previous results on galactosyl-lactose conversions, showing a much
higher specificity constant (kcat/kM) for the transferase reaction to 3′-galactosyllactose
than for the reactions to 4′-galactosyllactose and 6′-galactosyllactose.[34] Closer inspection of the 1D1H NMR
profile of the Sia-LGOS fractions revealed the Bf4 signals
at δ 4.200–4.211, which originate from the LGOS4, LGOS5,
LGOS6, or LGOS7 structures (slightly shifted). This provided evidence
for the presence of the LGOS4, LGOS5, LGOS6, or LGOS7 compounds in
the Sia-LGOS mixture. Moreover, the 1H NMR spectrum of
this mixture showed anomeric C-1 signals (slightly shifted) at δ
4.694, 4.650, and 4.629 from the structures LGOS4–7.
Figure 5
HPAEC-PAD profiles
of compounds in (1) 1 mM LGOS incubation mixture
before purification to remove mono- and disaccharides and (2) Sia-LGOS
fraction after being desialylated by acetic acid (20%) treatment.
Identified peaks are marked corresponding to the structures shown
in Scheme . Peak 2
corresponds to the LGOS2a or LGOS2b structure. Peak 7 corresponds
to the LGOS7a or LGOS7b structure.
HPAEC-PAD profiles
of compounds in (1) 1 mM LGOS incubation mixture
before purification to remove mono- and disaccharides and (2) Sia-LGOS
fraction after being desialylated by acetic acid (20%) treatment.
Identified peaks are marked corresponding to the structures shown
in Scheme . Peak 2
corresponds to the LGOS2a or LGOS2b structure. Peak 7 corresponds
to the LGOS7a or LGOS7b structure.In LGOS5 (Gal(β1→3)Gal(β1→4)Fru)
and
LGOS7a (Gal(β1→3)Gal(β1→3)Gal(β1→4)Fru),
the O-3 positions of the internal β-Gal residues are already
substituted, only the terminal β-Gal residues of LGOS5 and LGOS7a
are available for (α2→3)-linked decoration with Neu5Ac
to yield the corresponding monosialylated oligosaccharides: Neu5Ac(α2→3)Gal(β1→3)Gal(β1→4)Fru
and Neu5Ac(α2→3)Gal(β1→3)Gal(β1→3)Gal(β1→4)Fru
(Scheme ). The structure
of LGOS4 (Gal(β1→4)Gal(β1→4)Fru) was only
monosialylated by TcTS, although it also possesses a nonsubstituted
O-3 of the internal β-Gal residue. This was also observed for
the similar structure β4′-galactosyl-lactose, of which
only the terminal β-Gal residue was (α2→3)-substituted
with Neu5Ac.[34] The disialylated LGOS fraction
was too minor to be elucidated. In the LGOS mixture, only LGOS1, LGOS2a,
and LGOS3, each with two terminal β-Gal residues, as well as
LGOS2b with an internal β-Gal residue (β1→6) linked
with a terminal β-Gal residue, are likely disialylated.[34]
Sialylation of GOS by TcTs
In our
previous work, the
VivinalGOS DP3 and DP4 fractions were sialylated using TcTS.[8] These sialylated mixtures were applied onto a
Resource Q anion-exchange-chromatography column to obtain the separate
monosialylated- and disialylated-GOS fractions, depending on the negative
charges.[8] The HPAEC-PAD profiles of the
sialylated GOS DP3 fraction showed the presence of multiple mono-Sia-GOS
compounds at retention times between 11 and 17 min and di-Sia-GOS
compounds at retention times between 16 and 23 min (Figure A,B). Similarly, in the HPAEC-PAD
profiles of the Sia-GOS DP4 fraction, the mono-Sia-GOS compounds eluted
at retention times between 8 and 13 min, and the di-Sia-GOS compounds
eluted at retention times between 17 and 23 min (Figure C,D). The Sia-GOS mixtures
were incubated with neuraminidase from Clostridium perfringens, which prefers to hydrolyze (α2→3)-linkages over (α2→6)-
and (α2→8)-linked sialic acids, to remove the sialic
acid groups attached to the GOS compounds. The HPAEC-PAD profiles
of the desialylated fractions were compared with those of the VivinalGOS mixture, which were previously annotated,[40,41] in order to identify decorated structures (Figure A1,B1). In the GOS DP3 fraction, at least
five structures were monosialylated, namely, GOS6a or 6b, GOS9, GOS10a
or 10b, GOS11, and GOS12 (Figure A2). At least three of these seven structures were
also found in the di-Sia-GOS fraction, namely, GOS6a or 6b, GOS9,
and GOS10a or 10b (Figure A3). In the GOS DP4 fraction, the structures GOS14a or 14b,
GOS15, GOS16, GOS17, and GOS18 were found to be monosialylated (Figure B2), and the structures
GOS14a, 14b, 15, and 16 were found to be disialylated (Figure B3). The possible positions
of sialic acid (α2→3)-linked to these GOS compounds are
presented in Scheme . As expected, the structures GOS6a, GOS9, GOS10a or 10b, GOS14a,
GOS14b, GOS15a or 15b, and GOS16a or 16b with two unsubstituted terminal
β-Gal residues at O-3 positions were either mono- or disialylated
by TcTS.[34] The disialylation of the structure
GOS6b (with an internal β-Gal residue linked (β1→6)
with a terminal β-Gal residue) by this trans-sialidase was already
observed in a previous study (Scheme ).[34] The linear Gal(β1→4)Gal
epitope present in the structures GOS11, 16c, 17, 18a, and 18b allowed
only the terminal β-Gal residue to be sialylated by TcTS, resulting
in only monosialylation for these types of structures (Scheme ).
Figure 6
HPAEC-PAD profiles of
the Sia-GOS (A,B) DP3 and (C,D) DP4 fractions.
Mono- and disialylated-GOS peaks are marked.
Figure 7
HPAEC-PAD profiles of compounds from sialylated-GOS fractions (A)
DP3 and (B) DP4: (1) neutral GOS mixtures at corresponding DP, (2)
mono-Sia-GOS, and (3) di-Sia-GOS fractions after being desialylated.
Identified GOS peaks are marked with numbers as used by van Leeuwen
et al.,[40] corresponding with those in Scheme . Peak 6 corresponds
to GOS6a or 6b; peak 10 corresponds to GOS10a or 10b; peak 15 corresponds
to GOS15a or 15b; peak 16 corresponds to GOS16a, 16b, or 16c; and
peak 18 corresponds to GOS18a or 18b.
Scheme 3
Schematic Presentation
of the Possible Structures of the 16–39
(α2→3)-Sialylation Products of the Vivinal GOS DP3 and
DP4 Fractions
HPAEC-PAD profiles of
the Sia-GOS (A,B) DP3 and (C,D) DP4 fractions.
Mono- and disialylated-GOS peaks are marked.HPAEC-PAD profiles of compounds from sialylated-GOS fractions (A)
DP3 and (B) DP4: (1) neutral GOS mixtures at corresponding DP, (2)
mono-Sia-GOS, and (3) di-Sia-GOS fractions after being desialylated.
Identified GOS peaks are marked with numbers as used by van Leeuwen
et al.,[40] corresponding with those in Scheme . Peak 6 corresponds
to GOS6a or 6b; peak 10 corresponds to GOS10a or 10b; peak 15 corresponds
to GOS15a or 15b; peak 16 corresponds to GOS16a, 16b, or 16c; and
peak 18 corresponds to GOS18a or 18b.Close inspection of the HPAEC-PAD profiles (Figure A) showed in the VivinalGOS
DP3 fraction
only trace amounts of GOS12 (3′-galactosyllactose) and a major
peak for GOS11 (4′-galactosyllactose). After desialylation
of the monosialylated DP3 pool, approximately equal amounts of GOS11
and GOS12 were observed. This fits with observations on LGOS and previous
work, showing a higher specificity constant of TcTS toward 3′-galactosyllactose
than toward 4′-galactosyllactose.[34] Also, in the DP4 fraction (Figure B), the linear structures with terminal Gal(β1→4)
residues (GOS17 and GOS18) showed relatively low peaks, compared with
those of the VivinalGOS DP4 pool, whereas the branched structures
had relatively increased.In this study, the trans-sialidase
from T. cruzi was used to transfer sialic acid to
oligosaccharides (DP3–4)
in GL34, LGOS, and VivinalGOS mixtures.[8] Decorated structures were identified by HPAEC-PAD chromatography
and NMR spectroscopy. As expected, various compounds in these mixtures
with one or more accessible β-Gal-OH-3 groups were used as acceptor
substrates by TcTS. The F2 (2-Glc-Lac) compound in the GL34 mixture
was monosialylated, yielding α3Sia-2-Glc-Lac with a conversion
degree of 47.6%. TcTS was able to transfer sialic acid to at least
five different compounds in the LGOS mixture with a conversion degree
of up to 52%. The conversion of galacto-oligosaccharides (GOS) with
DP3–4 (3 mM GOS with 6 mM (α2→3)-linked Neu5Ac)
into Sia-GOS by TcTS was clearly lower, at about 35%, but it was obtained
under different conditions.[8] The optimal
concentrations of the GL34 and LGOS mixtures for maximal conversion
by TcTS (10 μg mL–1) in the incubations with
5 mM (α2→3)-linked Neu5Ac (from GMP) were 10 and 1 mM,
respectively. In fact, all the structures in the LGOS mixture possess
terminal nonreducing β-Gal residues, whereas only the F2 compound
of the GL34 mixture has a terminal β-Gal residue. Previously,
only lactulose was used as an acceptor substrate for a mutant trans-sialidase
Tr13 from T. rangeli.[42] The GOS mixture has been known to provide multiple C-3 hydroxyl
groups and to be an easily accessible substrate for trans-sialidase,
including TcTS (acceptor) sites.[9,8,43] Our study showed that in fact most of the GOS structures of DP3
and DP4 from VivinalGOS were sialylated by TcTS. Moreover, the results
revealed a strong preference for terminal β-Gal residues to
be sialylated. Only branched compounds with two nonreducing terminal
β-Gal residues were disialylated. The only exception known so
far is 6′-galactosyllactose, which is linear with a specific
Gal(β1→6)Gal epitope that could be disialylated by TcTS.[34] Moreover, our study showed that structures with
a Gal(β1→3) terminal residues were more efficiently sialylated
by TcTS.In conclusion, the data show that enzymatic synthesis
of sialylated
lactose- and lactulose-derived oligosaccharides, using the TcTS enzyme
and (α2→3)-Neu5Ac from GMP as a donor substrate, yields
a highly interesting variety of sialylated oligosaccharides. This
transfer of sialic acid as a functional group is the first step in
developing hMOS-mimicking compounds. In future studies,
we aim to optimize their biosynthesis and to evaluate the potential
use of these novel compounds for pathogen inhibition and prevention
of NEC.
Authors: María Fernanda Amaya; Andrew G Watts; Iben Damager; Annemarie Wehenkel; Tong Nguyen; Alejandro Buschiazzo; Gastón Paris; A Carlos Frasch; Stephen G Withers; Pedro M Alzari Journal: Structure Date: 2004-05 Impact factor: 5.006
Authors: G Boehm; M Lidestri; P Casetta; J Jelinek; F Negretti; B Stahl; A Marini Journal: Arch Dis Child Fetal Neonatal Ed Date: 2002-05 Impact factor: 5.747
Authors: F Vandekerckhove; S Schenkman; L Pontes de Carvalho; S Tomlinson; M Kiso; M Yoshida; A Hasegawa; V Nussenzweig Journal: Glycobiology Date: 1992-12 Impact factor: 4.313
Authors: Andrew G Watts; Iben Damager; Maria L Amaya; Alejandro Buschiazzo; Pedro Alzari; Alberto C Frasch; Stephen G Withers Journal: J Am Chem Soc Date: 2003-06-25 Impact factor: 15.419
Authors: Sander S van Leeuwen; Evelien M Te Poele; Anastasia Chrysovalantou Chatziioannou; Eric Benjamins; Alfred Haandrikman; Lubbert Dijkhuizen Journal: J Agric Food Chem Date: 2020-11-03 Impact factor: 5.279